Prisma and extend 2.0 follow-up of study participants
Active Awarded Last action
- Contract number
- 75N91023F00001
- Awardee
-
Fundacion Inciensa UEI KDL2VERNRKA5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,981,172
Award facts
- Contract value 100% obligated
- $6,981,172.00 Current and potential, with all options
- Completion date 93% complete
- Current and potential, with all options
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Sealed Bid
- Pricing
- Firm Fixed Price
- Place of performance
- Costa Rica
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $1,451,361 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,401,675 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,684,414 | |
| Original award | $1,443,722 |
About this award
The National Cancer Institute awarded a $6.98 million firm fixed-price delivery order to Fundacion Inciensa for the PRISMA and EXTEND 2.0 Follow-up of Study Participants program. This delivery order, issued on February 1, 2023, with an ultimate completion date of January 31, 2027, is part of a larger $49 million Indefinite Delivery Contract (IDC) established between NCI and the Costa Rica-based research foundation. Fundacion Inciensa, a non-profit organization registered in the System for Award Management since 2004, will perform work at its location in Costa Rica and leverage its expertise in epidemiological, clinical, and laboratory research services. The award carries no set-aside designation and represents continuation of the organizations's established partnership with NCI focused on infectious disease research and vaccine studies.
This delivery order supports NCI's long-term research objectives in human papillomavirus vaccine trials and related epidemiological investigations through ongoing follow-up with study participants. Fundacion Inciensa has demonstrated consistent capability in this specialized field, having previously received multiple prime contract awards from NCI totaling approximately $36 million. The organization's federal contract history reflects sustained expertise in conducting clinical trials, collecting and analyzing research data, performing laboratory testing, and evaluating vaccine efficacy and disease transmission patterns. The firm fixed-price structure and delivery order vehicle provide NCI with flexibility to manage research timelines while maintaining cost certainty for this critical continuation work.
Quick answers
Who was awarded contract 75N91023F00001?
75N91023F00001 was awarded to Fundacion Inciensa by National Cancer Institute (National Institutes of Health) on February 1, 2023.
How much is contract 75N91023F00001 worth?
The government has obligated $6,981,172 on 75N91023F00001.
Is contract 75N91023F00001 an order under another contract?
Yes. 75N91023F00001 is a delivery order under HHSN261201700012I, an indefinite delivery contract.
Was contract 75N91023F00001 competed?
The extent of competition for 75N91023F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award